Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

Offbeat, anarchic, and allergic to laugh tracks — these sitcoms carry Malcolm’s torch of domestic mayhem and adolescent ...